The drug helped patients reduce their weight by only 22.7 per cent, falling short of the anticipated result. Novo’s shares ...

Around the holidays – when many people are baking cookies for Santa, enjoying cocktail parties or having festive family feasts – some adults who use popular medications for diabetes or weight loss ...

Tiny doses of the weight-loss drug can sidestep its unpleasant side effects, say influencers. But is customising the dose a ...

Trials of semaglutide in patients with Alzheimer’s and CagriSema in obese patients diabetes could give investors reason to be optimistic, Intron Health’s analysts said ...

The U.S. Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the ...

Asian and European stock markets were largely getting off to a good start to a holiday-shortened Christmas week. Bargain hunting was in evidence as Novo Nordisk rose following a sharp drop for the ...

The statistics continue to be alarming, with no indication that the global rise in obesity is slowing. The real question ...

Hims & Hers is transforming telehealth with personalized medications, rapid subscription growth, and strong financials, poised for market leadership. Read more here.

Additionally, AbbVie is an exceptional income stock. It's a Dividend King, with 52 consecutive years of payout increases ...

The study highlighted interventions to reduce heart failure risk — most notably hypertension control and weight loss.

In a recent head-to-head study involving Novo Nordisk 's Wegovy, Zepbound came out on top, resulting in average weight loss ...

After falling behind 3-0 against Williamsport on Sunday, Hughesville senior Deja Roark would help the Spartans quickly take ...